Conversely, patients with RAD21 and SMC1A/SMC3/PDS5B mutations presented more frequently with de novo AML with NPM1 mutations (27/69 (39%), 2/12 (17%), 3/11(27%), and 2/6 (33%) cases, respectively) versus STAG2-mutant patients (p < 0.0001). This evidence concerns the gene SMC3 and acute myeloid leukemia.